PRESS RELEASE published on 05/02/2023 at 23:15, 1 year 4 months ago Moderna Announces Establishment of an Enterprise Solutions Hub and Commercial Operations in The Philippines
PRESS RELEASE published on 04/20/2023 at 22:05, 1 year 5 months ago Moderna to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023
PRESS RELEASE published on 04/20/2023 at 13:30, 1 year 5 months ago Moderna and IBM to Explore Quantum Computing and Generative AI for mRNA Science
PRESS RELEASE published on 04/16/2023 at 17:00, 1 year 5 months ago Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following C
PRESS RELEASE published on 04/11/2023 at 13:00, 1 year 5 months ago Moderna Announces Clinical and Program Updates at 4th Vaccines Day
PRESS RELEASE published on 04/06/2023 at 23:00, 1 year 5 months ago MRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melan
PRESS RELEASE published on 03/30/2023 at 13:00, 1 year 5 months ago Moderna Finalizes Agreement with the Government of the Republic of Kenya to Establish an mRNA Manufacturing Facility
PRESS RELEASE published on 03/24/2023 at 12:30, 1 year 6 months ago Moderna to Host Fourth Annual Virtual Vaccines Day on April 11, 2023
PRESS RELEASE published on 03/23/2023 at 12:02, 1 year 6 months ago Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines
PRESS RELEASE published on 03/14/2023 at 22:40, 1 year 6 months ago Moderna Announces Phase 2 Data on mRNA-4157/V940, an Investigational mRNA Personalized Cancer Vaccine, to be Presented at the 2023 AACR Annual Meeting
Published on 09/28/2024 at 02:06, 1 day 1 hour ago Global Education Communities Corp. Reports Second Tranche Closing of Non-Brokered Private Placement
Published on 09/28/2024 at 02:00, 1 day 1 hour ago bettermoo(d)’s Moodrink(TM) Featured in Banners of Well-Known Canadian Retailers
Published on 09/28/2024 at 00:10, 1 day 3 hours ago LQWD Technologies Announces Non-Brokered Private Placement Update
Published on 09/28/2024 at 14:01, 13 hours 35 minutes ago Turkiye Garanti Bankasi A.S.: Explanation on Subordinated Debt Securities to Qualified Investors
Published on 09/27/2024 at 22:30, 1 day 5 hours ago DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update
Published on 09/27/2024 at 21:56, 1 day 5 hours ago EQS-Adhoc: FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
Published on 09/27/2024 at 18:50, 1 day 8 hours ago PETROFAC ANNOUNCES IN-PRINCIPLE AGREEMENT ON FINANCIAL RESTRUCTURE
Published on 09/27/2024 at 18:40, 1 day 8 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/27/2024 at 17:45, 1 day 9 hours ago NFL BIOSCIENCES: 2024 FIRST-HALF BUSINESS AND EARNINGS UPDATE
Published on 09/26/2024 at 18:00, 2 days 9 hours ago GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2024
Published on 09/26/2024 at 18:00, 2 days 9 hours ago GUILLEMOT CORPORATION: 2024 CONSOLIDATED INTERIM RESULTS
Published on 09/26/2024 at 17:47, 2 days 9 hours ago imerys-26-September-2024-information-share-capital-and-voting-rights-as-of-31-August-2024